A new drug reduces risk of psychosis relapse in patients with dementia
Read now →Pimavanserin has not received approval from the FDA, but study results are encouraging
Soren Emerson
Neuroscience
Vanderbilt University
Soren Emerson is a an entering first year PhD student in the Vanderbilt University neuroscience program. He previously attended, and graduated from, Davidson College with a B.S. in neuroscience. He conducted three years of independent research at Davidson College under the mentorship of Dr. Mark Smith, a behavioral pharmacologist, and Dr. Rachid El Bejjani, a C. elegans neurobiologist. His research modeled the genetic and molecular mechanism of cocaine in C. elegans and the results of the project yielded a first author publication. At Vanderbilt, Soren plans to continue his research career in neuropharmacology.
Pimavanserin has not received approval from the FDA, but study results are encouraging
New research compared the "magic mushrooms" component to Lexapro
A large-scale study shows how the opioid epidemic has created downstream negative health outcomes
Doctors do not currently monitor a person's circadian rhythms because there is not an efficient way to measure them
Up to five cups of coffee per day seems to be fine. Six or more? Your brain is going to feel it
New research uncovers a link between cocaine and acetylcholine that could eventually lead to new treatments for addiction
The story behind these numbers is complex, but opioids have played a major role
Could these resins also be used to treat epilepsy in humans?
A small clinical trial shows promise for people who don't find relief from antidepressants
Not so fast. We should be wary of trying to science our way out of large-scale health issues
A data-driven search found a compound that shows promising results in early trials
People who had COVID-19 may need long-term care — the US healthcare system isn't ready
To explain where SARS-CoV-2 came from, look at processes with scientific explanations and precedents